Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

BACKGROUND: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. Af...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Bijal D, Cassaday, Ryan D, Park, Jae H, Houot, Roch, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick J, Jeyakumar, Deepa, Mao, Daqin, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C, Damico Khalid, Rita, Ghobadia, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471850/
https://www.ncbi.nlm.nih.gov/pubmed/37648261
http://dx.doi.org/10.1136/jitc-2023-007118

Ejemplares similares

Ejemplares similares